Open an account

Sangamo Therapeutics

SGMO · NASDAQ

$0.11+$0.0088 (+8.70%)TodayMarket closed ·
Prev close $0.1012

About SGMO

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Employees
142
Headquarters
Richmond California, California
Listed
Apr 6, 2000
Sector
Health Care
Industry
Biotechnology
Website
sangamo.com

SGMO key statistics

Market cap
29.47M
Price-earnings ratio
—
Dividend yield
—
Average volume
2.18M
Volume
360.93K
Open price
$0.085
High today
$0.11
Low today
$0.085
52 Week high
$0.7191
52 Week low
$0.01

Sangamo Therapeutics (SGMO) at a glance

As of Oct 20, 2026, Sangamo Therapeutics (SGMO) shares are priced at $0.11, giving the company a market cap of 29.47M.

Today the stock has traded between $0.085 and $0.11. The current price is 29.4% above the day's low and 0.0% below its high.

Volume so far is 360.93K shares, below the average of 2.18M shares a day.

Over the past year Sangamo Therapeutics has ranged from $0.01 to $0.7191, and now sits 14% of the way up that range.

Sangamo Therapeutics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q1 FY26 it reported -$0.08 per share against an estimate of $0.0051.

The average analyst price target is $2.61, 2276.1% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 6 analystsAvg $2.61
Low
$1.26
Now
$0.11
High
$5.25

SGMO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 138.0% on average.

  1. Q2 FY24: reported -$0.18 per share against an estimate of -$0.1486
  2. Q3 FY24: reported $0.04 per share against an estimate of -$0.0291
  3. Q4 FY24: reported -$0.11 per share against an estimate of -$0.0931
  4. Q1 FY25: reported -$0.14 per share against an estimate of -$0.1333
  5. Q2 FY25: reported -$0.08 per share against an estimate of -$0.1301
  6. Q3 FY25: reported -$0.11 per share against an estimate of $0.0002
  7. Q4 FY25: reported -$0.11 per share against an estimate of -$0.0612
  8. Q1 FY26: reported -$0.08 per share against an estimate of $0.0051

SGMO news

  • Vandana Singh

    Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle

  • Caroline Ryan

    Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth Bankruptcy

  • Press releaseGlobe Newswire

    How Advanced Drug Delivery Could Improve Existing Cancer Treatments

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Avi Kapoor

    Crude Oil Jumps 5%; Automatic Data Processing Posts Upbeat Earnings

  • Avi Kapoor

    Dow Falls 100 Points; Brinker Earnings Beat Estimates

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Similar companies

Companies in the same industry as Sangamo Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.